{
    "xml": "<topic id=\"PHP3874\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/telbivudine\" basename=\"telbivudine\" title=\"TELBIVUDINE\">\n<title>TELBIVUDINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1112\" namespace=\"/interactions/list-of-drug-interactions/antivirals/telbivudine\">Telbivudine</xref>\n</p>\n<data name=\"vtmid\">424071004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_298642086\" title=\"Nucleoside analogues\">Nucleoside analogues</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP42616\" outputclass=\"indicationsAndDose\" rev=\"1.13\" parent=\"/drugs/telbivudine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis, when other treatment is not appropriate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42638\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/telbivudine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Lamivudine-resistant chronic hepatitis B&#8212;risk of telbivudine resistance</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42612\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/telbivudine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (telbivudine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42592\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/telbivudine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">raised serum amylase</ph>; <ph outputclass=\"sideEffect\">raised serum lipase</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arthralgia</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">myopathy (discontinue treatment)</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Lactic acidosis</ph>; <ph outputclass=\"sideEffect\">rhabdomyolysis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42609\" outputclass=\"pregnancy\" parent=\"/drugs/telbivudine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42641\" outputclass=\"breastFeeding\" parent=\"/drugs/telbivudine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42602\" outputclass=\"renalImpairment\" parent=\"/drugs/telbivudine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>600&#8239;mg every 48 hours if eGFR 30&#8211;49&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 600&#8239;mg every 72 hours if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42567\" outputclass=\"monitoringRequirements\" parent=\"/drugs/telbivudine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function tests every 3 months and viral markers of hepatitis B every 3&#8211;6 months during treatment (continue monitoring for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42607\" outputclass=\"patientAndCarerAdvice\" rev=\"1.12\" parent=\"/drugs/telbivudine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Muscle effects and peripheral neuropathy</p>\n<p>Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42542\" outputclass=\"nationalFunding\" rev=\"1.17\" parent=\"/drugs/telbivudine\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA154</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Telbivudine for chronic hepatitis B (August 2008)</p>\r\n<p>Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA154\">www.nice.org.uk/TA154</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3874-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/telbivudine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76658\" title=\"Tablet\" namespace=\"/drugs/telbivudine/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78240\" namespace=\"/treatment-summaries/hepatitis\" title=\"Hepatitis\" count=\"3\" rel=\"backlink\">Hepatitis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1112\" namespace=\"/interactions/list-of-drug-interactions/antivirals/telbivudine\" title=\"Telbivudine\" count=\"1\" rel=\"link\">Telbivudine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76658\" namespace=\"/drugs/telbivudine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP3874",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/telbivudine",
    "basename": "telbivudine",
    "title": "TELBIVUDINE",
    "interactants": [
        {
            "id": "bnf_int_1112",
            "label": "Telbivudine"
        }
    ],
    "vtmid": "424071004",
    "drugClassification": [
        "Nucleoside analogues"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis, when other treatment is not appropriate",
                        "html": "Chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis, when other treatment is not appropriate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "600 mg once daily.",
                        "html": "<p>600&#8239;mg once daily.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Lamivudine-resistant chronic hepatitis B&#8212;risk of telbivudine resistance",
                "html": "Lamivudine-resistant chronic hepatitis B&#8212;risk of telbivudine resistance"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.",
                "html": "<p>Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (telbivudine).",
                "html": "<p>Appendix 1 (telbivudine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised serum amylase",
                        "html": "raised serum amylase",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised serum lipase",
                        "html": "raised serum lipase",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Arthralgia",
                        "html": "Arthralgia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "myopathy (discontinue treatment)",
                        "html": "myopathy (discontinue treatment)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Lactic acidosis",
                        "html": "Lactic acidosis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rhabdomyolysis",
                        "html": "rhabdomyolysis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "600 mg every 48 hours if eGFR 30&#8211;49 mL/minute/1.73 m2; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>600&#8239;mg every 48 hours if eGFR 30&#8211;49&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 600&#8239;mg every 72 hours if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function tests every 3 months and viral markers of hepatitis B every 3&#8211;6 months during treatment (continue monitoring for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation.",
                "html": "<p>Monitor liver function tests every 3 months and viral markers of hepatitis B every 3&#8211;6 months during treatment (continue monitoring for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Muscle effects and peripheral neuropathy",
                "textContent": "Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.",
                "html": "<p>Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA154",
                        "label": "www.nice.org.uk/TA154"
                    }
                ],
                "fundingIdentifier": "NICE TA154",
                "textContent": "Telbivudine for chronic hepatitis B (August 2008) Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA154",
                "html": "<p outputclass=\"title\">Telbivudine for chronic hepatitis B (August 2008)</p> <p>Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA154\">www.nice.org.uk/TA154</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76658",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78240",
                "label": "Hepatitis",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1112",
                "label": "Telbivudine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76658",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}